Results 101 to 110 of about 15,380 (223)

Clinical outcomes of FOLFIRINOX in locally advanced pancreatic cancer: A single center experience [PDF]

, 2018
Systemic chemotherapy or chemoradiotherapy is the initial primary option for patients with locally advanced pancreatic cancer (LAPC). This study analyzed the effect of FOLFIRINOX and assessed the factors influencing conversion to surgical resectability ...
Gromski, Mark A., Hwang, Jin-Hyeok, Kim, Hyoung Woo, Kim, Jaihwan, Kim, Jinwon, Lee, Jong-chan, Lee, Jongchan   +6 more
core   +1 more source

Computed Tomography Scans in the Prediction of Margin‐Negative Resection in Pancreatic Cancer Following Neoadjuvant Treatment: An Updated Systematic Review and Meta‐Analysis

iRADIOLOGY, Volume 4, Issue 2, Page 147-156, April 2026.
In this systematic review and meta‐analysis which evaluated the role of CT scan in the prediction of margin‐negative resection in pancreatic cancer following neoadjuvant treatment, the pooled sensitivity was 0.50 (95% CI: 0.34–0.66), and the pooled specificity was 0.75 (95% CI: 0.61–0.85).
Ehsan Emami, Dina Seyedi, Alireza Hassanpour, Faizan Bashir, Elina Attaran, Maryam Mostofi, Mohammadjavad Abbaspour, Farzin Tahmasbi Arashlow, Pariya Zibaei, Alaleh Alizadeh, Neda Tizro, Arash Saberian, Komeil Aghazadeh‐Habashi, Masoud Noroozi, Niloofar Deravi   +14 more
wiley   +1 more source

Nationwide trends in chemotherapy use and survival of elderly patients with metastatic pancreatic cancer [PDF]

, 2017
Despite an aging population and underrepresentation of elderly patients in clinical trials, studies on elderly patients with metastatic pancreatic cancer are scarce.
Besselink, M.G. (Marc), Haj Mohammad, N. (Nadia), Laarhoven, H.W.M. (Hanneke) van, Lemmens, V.E.P.P. (Valery), Portielje, J.E.A. (Johanneke ), van der Geest, L.G.M. (Lydia G.M.), Wilmink, J.W. (Johanna)   +6 more
core   +3 more sources

Challenges of drug resistance in the management of pancreatic cancer [PDF]

, 2010
The current treatment of choice for metastatic pancreatic cancer involves single agent gemcitabine or combination of gemcitabine with capecitabine and erlotinib (tyrosine kinase inhibitor).
Akada, Allison, Almoguera, Andreetta, Arai, Arlt, Arteaga, Arumugam, Asano, Bachem, Baldwin, Banerjee, Bartsch, Bergers, Best, Bold, Bondar, Buck, Burris, Chakravarti, Chakravarti, Choi, Cunningham, Cunningham, Dancer, Dong, Duxbury, Duxbury, Duxbury, Duxbury, Engelman, Feldmann, Ferrero, Galmarini, Geyer, Giovannetti, Goan, Greer, Hagmann, Hahn, Henke, Hruban, Humeniuk, Ischenko, Ishikawa, Itoi, Jansen, Karapetis, Kindler, Kong, Koopman, Kulik, Lei, Lemoine, Liau, Liau, Longley, Mackey, Mackey, Mackey, Mahon, Mamaghani, Marechal, Marmor, Martin Clynes, Mata, Maxwell, Mendelsohn, Meropol, Miwa, Moertel, Molina-Arcas, Moore, Morgillo, Moriyama, Muerkoster, Muerkoster, Nakahira, Nakajima, Nakano, Naomi Walsh, Nishimura, Oguri, Okamoto, Okumura, Olive, O’Driscoll, Pao, Park, Park, Peters, Plunkett, Ray McDermott, Ritzel, Rizwan Sheikh, Robert O’Connor, Ruggeri, Safran, Saito, Sakamoto, Schuller, Sebastiani, Shah, Shi, Simon, Spratlin, Takao, Takebayashi, Treat, Tsukamoto, Tzeng, Vaishampayan, Van Cutsem, van der Wilt, Wang, Wang, Wang, Xiong, Yamasaki, Yokoi   +119 more
core   +1 more source

Perioperative Clinical Usage of Phellinus Linteus as a Nutraceutical for Non-FOLFIRINOX-Based Postoperative Adjuvant Chemotherapy for Resected Pancreatic Cancer: A Retrospective Cohort Study

Integrative Cancer Therapies
Introduction: Most patients with pancreatic cancer experience systemic recurrence within 1 to 2 years after radical pancreatectomy. Phellinus linteus (PL) has demonstrated anti-inflammatory, antioxidant, and anti-cancer properties, suggesting potential ...
Juwan Kim MD, Seung Soo Hong MD, Sung Hyun Kim MD, MS, Ho Kyoung Hwang MD, PhD, Chang Moo Kang MD, PhD   +4 more
doaj   +1 more source

The Potential for Circulating Tumor Cells in Pancreatic Cancer Management. [PDF]

, 2017
Pancreatic cancer is one the most lethal malignancies. Only a small proportion of patients with this disease benefit from surgery. Chemotherapy provides only a transient benefit.
Michael Pimienta, Michael Pimienta, Mouad Edderkaoui, Ruoxiang Wang, Stephen Pandol   +4 more
core   +2 more sources

Selection of optimal molecular targets for tumor-specific imaging in pancreatic ductal adenocarcinoma [PDF]

, 2017
Discrimination of pancreatic ductal adenocarcinoma (PDAC) from chronic pancreatitis (CP) or peritumoral inflammation is challenging, both at preoperative imaging and during surgery, but it is crucial for proper therapy selection. Tumor-specific molecular
Bonsing, B.A. (Bert), Boonstra, M.C. (M.), Eijck, C.H.J. (Casper) van, Fariña-Sarasqueta, A. (Arantza), Kuppen, P.J.K. (P. J K), Mieog, J.S.D. (Sven), Morreau, H. (Hans), Prevoo, H.A. (Hendrica A.), Sier, C.F.M. (Cornelis), Swijnenburg, R.-J. (Rutger-Jan), Tummers, W.S. (Willemieke S.), Vahrmeijer, A.L. (Alexander L.), Velde, C.J.H. (Cornelis) van de   +12 more
core   +1 more source

Markov decision analysis of neoadjuvant treatment pathway versus surgery first pathway for resectable pancreatic cancer [PDF]

, 2018
Background: Surgery first (SF) versus neoadjuvant approach (NAT) to management of potentially resectable pancreatic ductal adenocarcinoma (PDAC) is controversial.
Bradley, Alison, Carter, Ross, Dickson, Euan J, Jamieson, Nigel B, McKay, Colin J, Van Der Meer, Robert   +5 more
core   +2 more sources

Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. [PDF]

, 2019
BackgroundTreatment outcomes for patients with advanced pancreatic ductal adenocarcinoma (PDAC) remain dismal. There are unmet needs for understanding the biologic basis of this malignancy using novel next-generation sequencing technologies.
Fanta, Paul, Kato, Shumei, Kurzrock, Razelle, Lanman, Richard B, Okamura, Ryosuke, Patel, Charmi, Patel, Hitendra, Raymond, Victoria M   +7 more
core   +1 more source

A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial. [PDF]

, 2017
Lessons learnedThe addition of the heat shock protein 27 (Hsp27)-targeting antisense oligonucleotide, apatorsen, to a standard first-line chemotherapy regimen did not result in improved survival in unselected patients with metastatic pancreatic cancer ...
Al-Hazzouri, Ahmed, Bendell, Johanna C, DeBusk, Laura M, Earwood, Chris, Guo, Shuangli, Ko, Andrew H, Lane, Cassie M, Murphy, Patrick B, Peyton, James D, Rodriguez, Francisco A, Shipley, Dianna L, Tempero, Margaret A, Waterhouse, David M, Womack, Mark S, Xiong, Henry Q   +14 more
core   +1 more source